COVID-19 vaccine: Potential coronavirus vaccine candidate from China shows promise in animal tests

More than 100 potential COVID-19 vaccines are in various stages of development around the world.

Reuters June 10, 2020 15:41:35 IST
COVID-19 vaccine: Potential coronavirus vaccine candidate from China shows promise in animal tests

A potential COVID-19 vaccine being developed by Chinese researchers showed promise in trials in monkeys, triggering antibodies and raising no safety issues, researchers said, and a human trial with more than 1,000 participants is under way.

The vaccine candidate, called BBIBP-CorV, induced high-level neutralising antibodies that can block the virus from infecting cells in monkeys, rats, guinea pigs and rabbits, researchers said in a paper published in online by the medical journal Cell on Saturday.

“These results support the further evaluation of BBIBP-CorV in a clinical trial,” researchers said in the paper.

BBIBP-CorV, developed by Beijing Institute of Biological Products affiliated to state-owned China National Pharmaceutical Group (Sinopharm), is among five candidates China is testing in humans.

COVID19 vaccine Potential <span class=coronavirus vaccine candidate from China shows promise in animal tests" width="1280" height="720" />

A vaccine is yet to be developed to prevent further spread of COVID-19 , but a lot of effort and financing is going into the effort.

More than 100 potential COVID-19 vaccines are in various stages of development around the world. Among front runners currently in human trials are being developed by AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and China’s CanSino Biologics.

As well as appearing safe and able to generate an immune response in animals, BBIBP-CorV did not appear to trigger antibodies that could boost the infection – a phenomenon known as antibody-dependent enhancement (ADE) – the researchers said, although this does not necessarily guarantee ADE won’t occur in human tests.

Apart from BBIBP-CorV, Sinopharm, which has invested 1 billion yuan ($141.40 million) in vaccine projects, is testing in humans another vaccine candidate developed by its Wuhan-based unit. The two shots have been given to more than 2,000 people in clinical trials.

Updated Date:

also read

Premier League: Nearly seven in 10 players double-jabbed against coronavirus
Sports

Premier League: Nearly seven in 10 players double-jabbed against coronavirus

"The Premier League can confirm today that 81 percent of players have received at least one COVID-19 vaccination dose, with 68 percent now fully vaccinated," the league said in a statement.

NBA: Brooklyn Nets say Kyrie Irving won't play or practice with team until he can do it full time
Sports

NBA: Brooklyn Nets say Kyrie Irving won't play or practice with team until he can do it full time

Without mentioning his vaccination status, general manager Sean Marks said Kyrie Irving has made a decision that keeps him from being able to perform with the team.

India logs 16,862 new COVID-19 cases, 379 deaths in past 24 hours; active infections lowest in 216 days
India

India logs 16,862 new COVID-19 cases, 379 deaths in past 24 hours; active infections lowest in 216 days

The national COVID-19 recovery rate is at 98.07 percent, the highest since March 2020, according to the health ministry